TDP-43 Phosphorylation-Blocking Peptides for Neurodegeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies are inadequate for effectively interrupting the phosphorylation and aggregation of TDP-43, which are key pathological features in neurodegenerative diseases such as ALS and FTD.
Innovation Solution
Development of peptides comprising a cell membrane penetration sequence and one or more TDP-43 phosphorylation-blocking sequences, which can interfere with the interaction between TDP-43 and CK1δ, thereby reducing TDP-43 phosphorylation and aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current strategies are used to interrupt TDP-43 phosphorylation and aggregation, then some level of intervention is achieved, but the strategies are inadequate for effectively blocking the pathological processes
Solution Approach 1:
The patent uses peptides as intermediary molecules that specifically bind to TDP-43 and block its phosphorylation by CK1δ kinase. These peptide intermediaries interfere with the pathological interaction between TDP-43 and phosphorylating enzymes, thereby effectively interrupting the phosphorylation and aggregation processes that current strategies fail to address adequately.
Solution Approach 2:
The invention changes the molecular parameters of intervention by using specifically designed peptides with particular amino acid sequences that match TDP-43 binding regions. This parameter change in the intervention molecule's structure enables highly specific and effective blocking of TDP-43 phosphorylation sites, overcoming the inadequacy of previous strategies.
2Reliability
If peptides with cell membrane penetration sequence and phosphorylation-blocking sequence are used, then TDP-43 phosphorylation and aggregation are effectively blocked, but the complexity of peptide design and delivery increases
Solution Approach 1:
The patent merges two functional sequences into a single peptide molecule: a cell membrane penetration sequence (such as TAT sequence) and a TDP-43 phosphorylation-blocking sequence. This combination allows the peptide to both enter cells efficiently and block TDP-43 phosphorylation, simplifying the delivery system while maintaining high effectiveness.
Solution Approach 2:
The designed peptides serve multiple functions simultaneously: they act as cell penetration vectors, specific blockers of TDP-43 phosphorylation, and inhibitors of TDP-43 aggregation. This multi-functionality reduces the need for separate delivery systems and auxiliary molecules, thereby managing complexity while achieving reliable therapeutic effects.
3Reliability
If peptides are designed to interfere with TDP-43 and CK1δ interaction, then phosphorylation is reduced, but the precision of targeting specific phosphorylation sites must be maintained
Solution Approach 1:
The patent applies local quality by designing peptide sequences that specifically target particular phosphorylation sites on TDP-43 (such as serine residues 409 and 410). The peptides are engineered with amino acid sequences that complement specific regions of TDP-43, ensuring precise localization and blocking of phosphorylation at critical sites while leaving other regions unaffected.
Solution Approach 2:
The invention uses peptide copies or mimics of the actual binding interface between TDP-43 and CK1δ. By creating simplified peptide versions that replicate the key interaction features, the system achieves precise targeting of phosphorylation sites without requiring the full complexity of the natural protein-protein interaction, thereby maintaining manufacturing precision.
Data Source
AI summary
Disclosed is a peptide including (a) a cell membrane penetration (CMP) sequence; and (b) one or more TDP-43 phosphorylation-blocking (PB) sequences. Also disclosed is a method of reducing the phosphorylation of TDP-43 in a cell, the method including: delivering an effective amount of a peptide to the cell, wherein the peptide comprises: (a) a cell membrane penetration (CMP) sequence; and (b) a TDP-43 phosphorylation-blocking (PB) sequence. Also disclosed is a method of treating a disease or pathological condition, the method comprising administering an effective amount of a peptide to a subject in need thereof; wherein the peptide comprises: (a) a cell membrane penetration (CMP) sequence; and (b) one or more TDP-43 phosphorylation-blocking (PB) sequences. Related uses, peptides for use, vectors, polynucleotide, and pharmaceutical compositions are disclosed.